Macquarie Initiates Coverage On Datadog with Neutral Rating, Announces Price Target of $85
Macquarie analyst Frederick Havemeyer initiates coverage on Datadog (NASDAQ:DDOG) with a Neutral rating and announces Price Target of $85.
Macquarie Initiates Coverage On CrowdStrike Holdings with Outperform Rating, Announces Price Target of $220
Macquarie analyst Frederick Havemeyer initiates coverage on CrowdStrike Holdings (NASDAQ:CRWD) with a Outperform rating and announces Price Target of $220.
Macquarie Initiates Coverage On Snowflake with Neutral Rating, Announces Price Target of $173
Macquarie analyst Frederick Havemeyer initiates coverage on Snowflake (NYSE:SNOW) with a Neutral rating and announces Price Target of $173.
Baird Initiates Coverage On Lineage Cell Therapeutics with Outperform Rating, Announces Price Target of $5
Baird analyst Jack Allen initiates coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Outperform rating and announces Price Target of $5.
Baird Initiates Coverage On Frequency Therapeutics with Outperform Rating, Announces Price Target of $10
Baird analyst Jack Allen initiates coverage on Frequency Therapeutics (NASDAQ:FREQ) with a Outperform rating and announces Price Target of $10.
Bernstein Initiates Coverage On Tilray Brands with Market Perform Rating, Announces Price Target of $3.9
Bernstein analyst Nadine Sarwat initiates coverage on Tilray Brands (NASDAQ:TLRY) with a Market Perform rating and announces Price Target of $3.9.
Evercore ISI Group Initiates Coverage On Legend Biotech with Outperform Rating
Evercore ISI Group analyst Umer Raffat initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Outperform rating.
Horizon Therapeutics Does Not Have Meaningful Upside, Analyst Initiating Coverage Says
HC Wainwright initiated coverage on Horizon Therapeutics plc (NASDAQ:HZNP) with a Neutral rating and a price target of $74. The analyst writes…
Loop Capital Initiates Coverage On Bionomics with Buy Rating, Announces Price Target of $23
Loop Capital analyst Esther Hong initiates coverage on Bionomics (NASDAQ:BNOX) with a Buy rating and announces Price Target of $23.
Raymond James Initiates Coverage On Parkit Enterprise with Market Perform Rating, Announces Price Target of C$1.1
Raymond James analyst Brad Sturges initiates coverage on Parkit Enterprise (TSXV:PKT) with a Market Perform rating and announces Price Target of C$1.1.